TY - JOUR T1 - Impact of COVID-19 on the diagnoses, HbA1c monitoring and mortality in people with type 2 diabetes: a UK-wide cohort study involving 13 million people in primary care JF - medRxiv DO - 10.1101/2020.10.25.20200675 SP - 2020.10.25.20200675 AU - Matthew J. Carr AU - Alison K. Wright AU - Lalantha Leelarathna AU - Hood Thabit AU - Nicola Milne AU - Naresh Kanumilli AU - Darren M. Ashcroft AU - Martin K. Rutter Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/27/2020.10.25.20200675.abstract N2 - Background The COVID-19 pandemic has already disproportionately impacted people with diabetes. Timely diagnosis and appropriate monitoring in people with type 2 diabetes (T2D) are necessary to reduce the risk of long-term complications.Methods We constructed a cohort of 23M patients using electronic health records from 1709 UK general practices registered with the Clinical Practice Research Datalink (CPRD), including 13M patients followed between March and July 2020. We compared trends in diagnoses, monitoring and mortality in T2D, before and after the first COVID-19 peak, using regression models and 10-year historical data. We extrapolated the number of missed or delayed diagnoses using UK Office for National Statistics data.Findings In England, rates of new T2D diagnoses were reduced by 70% (95% CI 68%-71%) in April 2020, with similar reductions in Northern Ireland, Scotland and Wales. Between March and July, we estimated that there were more than 45,000 missed or delayed T2D diagnoses across the UK. In April, rates of HbA1c testing in T2D were greatly reduced in England (reduction: 77% (95% CI 76%-78%)) with more marked reductions in Northern Ireland, Scotland and Wales (reduction: 84% (83-84%)). Reduced rates of diagnosing and HbA1c monitoring were particularly evident in older people, in males, and in those from deprived areas. Mortality rates in T2D in England were more than 2-fold higher (110%) in April compared to prior trends, but were only 66% higher in Northern Ireland, Scotland and Wales.Interpretation As engagement with the NHS increases, healthcare services will need to manage the backlog and the expected increase in T2D severity due to delayed diagnoses and reduced monitoring. Older people, men, and those from deprived backgrounds with T2D may be groups to target for early intervention.Funding National Institute for Health Research (NIHR) Greater Manchester Patient Safety Translational Research CentreCompeting Interest StatementAll authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years. DMA reports research funding from AbbVie, Almirall, Celgene, Eli Lilly, Novartis, Janssen, UCB and the Leo Foundation outside the submitted work. MKR has received consulting fees and non-promotional lecture fees from Novo Nordisk in relation to cardiovascular disease and diabetes. The company has had no role in influencing the proposed study and is not expected to benefit from this work. Outside the submitted work, MKR reports receiving research funding from Novo Nordisk, consultancy fees from Novo Nordisk and Roche Diabetes Care, and modest owning of shares in GlaxoSmithKline. NM reports honorarium for presentations from Napp Pharmaceuticals, Novo Nordisk, Sanofi, MyLan, Boehringer Ingelheim, Lilly Diabetes, Abbott, Omnia-Med, Takeda UK and AstraZeneca. All other authors declare no competing interests. There are no other relationships or activities that could appear to have influenced the submitted work.Funding StatementThis work was funded by the National Institute for Health Research (NIHR) Greater Manchester Patient Safety Translational Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study is based on data from the Clinical Practice Research Datalink obtained under license from the UK Medicines and Healthcare products Regulatory Agency. The study and use of CPRD data was approved by the Independent Scientific Advisory Committee for Clinical Practice Research Datalink research (protocol number: 20_182R).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe clinical codes used in this study are published on ClinicalCodes.org. Electronic health records are, by definition, considered "sensitive" data in the UK by the Data Protection Act and cannot be shared via public deposition because of information governance restriction in place to protect patient confidentiality. Access to data are available only once approval has been obtained through the individual constituent entities controlling access to the data. The primary care data can be requested via application to the Clinical Practice Research Datalink. https://www.cprd.com/ https://clinicalcodes.rss.mhs.man.ac.uk/ ER -